At #EBMT25, Mattia Algeri provided valuable insights into considerations for selecting patients with transfusion-dependent #thalassemia for allogeneic transplant or gene therapy.
Watch the exclusive interview here:
👉 buff.ly/CetMOvd
#BMTsm #Hematology #BloodSky #MedSky #HemeSky
Watch the exclusive interview here:
👉 buff.ly/CetMOvd
#BMTsm #Hematology #BloodSky #MedSky #HemeSky
May 13, 2025 at 2:05 PM
At #EBMT25, Mattia Algeri provided valuable insights into considerations for selecting patients with transfusion-dependent #thalassemia for allogeneic transplant or gene therapy.
Watch the exclusive interview here:
👉 buff.ly/CetMOvd
#BMTsm #Hematology #BloodSky #MedSky #HemeSky
Watch the exclusive interview here:
👉 buff.ly/CetMOvd
#BMTsm #Hematology #BloodSky #MedSky #HemeSky
Infections are the leading cause of non-relapse mortality in patients undergoing #CARTCell therapy.💉🩸
Learn more about this topic from Eleftheria Kampouri, whom we had the pleasure of speaking with at the #EBMT25 meeting:
👉 buff.ly/mRcSnju
#ImmunoOnc #HemOnc #BloodSky #MedSky #HemeSky
Learn more about this topic from Eleftheria Kampouri, whom we had the pleasure of speaking with at the #EBMT25 meeting:
👉 buff.ly/mRcSnju
#ImmunoOnc #HemOnc #BloodSky #MedSky #HemeSky
May 10, 2025 at 10:01 AM
Infections are the leading cause of non-relapse mortality in patients undergoing #CARTCell therapy.💉🩸
Learn more about this topic from Eleftheria Kampouri, whom we had the pleasure of speaking with at the #EBMT25 meeting:
👉 buff.ly/mRcSnju
#ImmunoOnc #HemOnc #BloodSky #MedSky #HemeSky
Learn more about this topic from Eleftheria Kampouri, whom we had the pleasure of speaking with at the #EBMT25 meeting:
👉 buff.ly/mRcSnju
#ImmunoOnc #HemOnc #BloodSky #MedSky #HemeSky
#EBMT25 | The lovely Manuela Spadea speaks about work investigating letermovir prophylaxis versus pre-emptive therapy in pediatric patients and the impact on immune reconstitution after alloSCT.
Click to watch the interview:
👉 buff.ly/ymsLIT1
#BMTsm #HemOnc #MedSky #BloodSky #Hematology
Click to watch the interview:
👉 buff.ly/ymsLIT1
#BMTsm #HemOnc #MedSky #BloodSky #Hematology
May 7, 2025 at 10:02 AM
#EBMT25 | The lovely Manuela Spadea speaks about work investigating letermovir prophylaxis versus pre-emptive therapy in pediatric patients and the impact on immune reconstitution after alloSCT.
Click to watch the interview:
👉 buff.ly/ymsLIT1
#BMTsm #HemOnc #MedSky #BloodSky #Hematology
Click to watch the interview:
👉 buff.ly/ymsLIT1
#BMTsm #HemOnc #MedSky #BloodSky #Hematology
"70% of patients with advanced systemic #Mastocytosis will have an SM component and an AHN component."
Hear as Deepti Radia discusses the diagnosis & management of SM with an associated hematologic neoplasm (AHN):
🎥 buff.ly/IjFJWyr
#MPNsm #HemOnc #EBMT25 #BloodSky #HemeSky #MedSky
Hear as Deepti Radia discusses the diagnosis & management of SM with an associated hematologic neoplasm (AHN):
🎥 buff.ly/IjFJWyr
#MPNsm #HemOnc #EBMT25 #BloodSky #HemeSky #MedSky
May 1, 2025 at 12:02 PM
"70% of patients with advanced systemic #Mastocytosis will have an SM component and an AHN component."
Hear as Deepti Radia discusses the diagnosis & management of SM with an associated hematologic neoplasm (AHN):
🎥 buff.ly/IjFJWyr
#MPNsm #HemOnc #EBMT25 #BloodSky #HemeSky #MedSky
Hear as Deepti Radia discusses the diagnosis & management of SM with an associated hematologic neoplasm (AHN):
🎥 buff.ly/IjFJWyr
#MPNsm #HemOnc #EBMT25 #BloodSky #HemeSky #MedSky
The FT14 study is evaluating the safety & efficacy of fludarabine plus treosulfan as a conditioning regimen in patients with AML.
The lovely Vera Radici shares the interim results of this study in a recent interview from #EBMT25:
🎥 buff.ly/oiJdymd
#BMTsm #Leusm #AMLsm
The lovely Vera Radici shares the interim results of this study in a recent interview from #EBMT25:
🎥 buff.ly/oiJdymd
#BMTsm #Leusm #AMLsm
April 30, 2025 at 10:11 AM
The FT14 study is evaluating the safety & efficacy of fludarabine plus treosulfan as a conditioning regimen in patients with AML.
The lovely Vera Radici shares the interim results of this study in a recent interview from #EBMT25:
🎥 buff.ly/oiJdymd
#BMTsm #Leusm #AMLsm
The lovely Vera Radici shares the interim results of this study in a recent interview from #EBMT25:
🎥 buff.ly/oiJdymd
#BMTsm #Leusm #AMLsm
At #EBMT25, Aldo Acosta-Medina shared insights into the clinical outcomes and treatment strategies for TA-TMA, outlining findings from the largest cohort of adult patients with TA-TMA to date!
Learn more by watching here:
👉 buff.ly/FPPGd6Z
#BMTsm #HemOnc #BloodSky #HemeSky #MedSky
Learn more by watching here:
👉 buff.ly/FPPGd6Z
#BMTsm #HemOnc #BloodSky #HemeSky #MedSky
April 26, 2025 at 3:02 PM
#EBMT25 | The wonderful Prof. Anna Sureda shares insight into the current landscape of conditioning regimens for patients with #lymphoma undergoing autologous or allogeneic stem cell transplantation:
👉 buff.ly/wVsfCTg 👈
#LYMsm #BMTsm #HemOnc #HodgkinLymphoma
👉 buff.ly/wVsfCTg 👈
#LYMsm #BMTsm #HemOnc #HodgkinLymphoma
April 23, 2025 at 10:01 AM
#EBMT25 | The wonderful Prof. Anna Sureda shares insight into the current landscape of conditioning regimens for patients with #lymphoma undergoing autologous or allogeneic stem cell transplantation:
👉 buff.ly/wVsfCTg 👈
#LYMsm #BMTsm #HemOnc #HodgkinLymphoma
👉 buff.ly/wVsfCTg 👈
#LYMsm #BMTsm #HemOnc #HodgkinLymphoma
Responses With Compassionate Use of MDC-CAR-BCMA001 Support Further Study in R/R Myeloma and AL Amyloidosis #EBMT25 #mmsm #hematology
www.onclive.com/view/respons...
www.onclive.com/view/respons...
Responses With Compassionate Use of MDC-CAR-BCMA001 Support Further Study in R/R Myeloma and AL Amyloidosis
Kiavasch Mohammad Nejad Farid, MD, discusses the signs of activity and safety with MDC-CAR-BCMA001 in pretreated patients with AL amyloidosis and myeloma.
www.onclive.com
April 17, 2025 at 3:03 PM
Responses With Compassionate Use of MDC-CAR-BCMA001 Support Further Study in R/R Myeloma and AL Amyloidosis #EBMT25 #mmsm #hematology
www.onclive.com/view/respons...
www.onclive.com/view/respons...
AlloSCT in advanced systemic #mastocytosis: who, when, and how? 🤔
These were all questions the lovely Deepti Radia answered in an interview at the recent #EBMT25 meeting!
Watch here for her valuable insight:
👉 buff.ly/XOYpBvQ 👈
#MPNsm #HemOnc #BMTsm #MedSky #BloodSky #HemeSky
These were all questions the lovely Deepti Radia answered in an interview at the recent #EBMT25 meeting!
Watch here for her valuable insight:
👉 buff.ly/XOYpBvQ 👈
#MPNsm #HemOnc #BMTsm #MedSky #BloodSky #HemeSky
April 15, 2025 at 1:04 PM
AlloSCT in advanced systemic #mastocytosis: who, when, and how? 🤔
These were all questions the lovely Deepti Radia answered in an interview at the recent #EBMT25 meeting!
Watch here for her valuable insight:
👉 buff.ly/XOYpBvQ 👈
#MPNsm #HemOnc #BMTsm #MedSky #BloodSky #HemeSky
These were all questions the lovely Deepti Radia answered in an interview at the recent #EBMT25 meeting!
Watch here for her valuable insight:
👉 buff.ly/XOYpBvQ 👈
#MPNsm #HemOnc #BMTsm #MedSky #BloodSky #HemeSky
The novel construct MDC-CAR-BCMA001 has shown impressive early efficacy in pts with heavily pretreated AL #amyloidosis & #myeloma.
We had the pleasure of hearing about this from Kiavasch Farid at #EBMT25!🎥
Watch here:
👉 buff.ly/9H15NXw
#MMSM #MultipleMyeloma #HemOnc #MedSky #BloodSky #HemeSky
We had the pleasure of hearing about this from Kiavasch Farid at #EBMT25!🎥
Watch here:
👉 buff.ly/9H15NXw
#MMSM #MultipleMyeloma #HemOnc #MedSky #BloodSky #HemeSky
April 14, 2025 at 12:02 PM
The novel construct MDC-CAR-BCMA001 has shown impressive early efficacy in pts with heavily pretreated AL #amyloidosis & #myeloma.
We had the pleasure of hearing about this from Kiavasch Farid at #EBMT25!🎥
Watch here:
👉 buff.ly/9H15NXw
#MMSM #MultipleMyeloma #HemOnc #MedSky #BloodSky #HemeSky
We had the pleasure of hearing about this from Kiavasch Farid at #EBMT25!🎥
Watch here:
👉 buff.ly/9H15NXw
#MMSM #MultipleMyeloma #HemOnc #MedSky #BloodSky #HemeSky
Nearly 3 years after treatment with cilta-cel, the risk of death was reduced by 45% compared with standard of care, according to long-term CARTITUDE-4 data #EBMT25
sohoinsider.com/news/cilta-c...
sohoinsider.com/news/cilta-c...
Cilta-cel cuts death risk by 45% vs standard care in myeloma
Cilta-cel cuts death risk by 45% vs standard care in myeloma, per CARTITUDE-4 study. OS, PFS, and QoL improved. EBMT 2025 results.
sohoinsider.com
April 9, 2025 at 7:43 PM
Nearly 3 years after treatment with cilta-cel, the risk of death was reduced by 45% compared with standard of care, according to long-term CARTITUDE-4 data #EBMT25
sohoinsider.com/news/cilta-c...
sohoinsider.com/news/cilta-c...
Want to hear about harnessing machine learning to predict outcomes post-alloSCT for patients with #myelofibrosis?🩸
We had the pleasure of catching up with Dr Adrian Mosquera-Orgueira at #EBMT25 to learn about this interesting topic!
Watch here:
🎥 buff.ly/7tAO9DJ
#MPNsm #MedSky #BloodSky #HemeSky
We had the pleasure of catching up with Dr Adrian Mosquera-Orgueira at #EBMT25 to learn about this interesting topic!
Watch here:
🎥 buff.ly/7tAO9DJ
#MPNsm #MedSky #BloodSky #HemeSky
April 9, 2025 at 9:09 AM
Want to hear about harnessing machine learning to predict outcomes post-alloSCT for patients with #myelofibrosis?🩸
We had the pleasure of catching up with Dr Adrian Mosquera-Orgueira at #EBMT25 to learn about this interesting topic!
Watch here:
🎥 buff.ly/7tAO9DJ
#MPNsm #MedSky #BloodSky #HemeSky
We had the pleasure of catching up with Dr Adrian Mosquera-Orgueira at #EBMT25 to learn about this interesting topic!
Watch here:
🎥 buff.ly/7tAO9DJ
#MPNsm #MedSky #BloodSky #HemeSky
Don't miss our excellent interview from the #EBMT25 meeting in which Marion Subklewe speaks on the classification & management of hematotoxicity after #CARTCell therapy.
Watch here:
👉 buff.ly/fyjvhML 👈
#ImmunoOnc #HemOnc #Hematology #MedSky #BloodSky #HemeSky #HemeOnc
Watch here:
👉 buff.ly/fyjvhML 👈
#ImmunoOnc #HemOnc #Hematology #MedSky #BloodSky #HemeSky #HemeOnc
April 8, 2025 at 12:01 PM
Don't miss our excellent interview from the #EBMT25 meeting in which Marion Subklewe speaks on the classification & management of hematotoxicity after #CARTCell therapy.
Watch here:
👉 buff.ly/fyjvhML 👈
#ImmunoOnc #HemOnc #Hematology #MedSky #BloodSky #HemeSky #HemeOnc
Watch here:
👉 buff.ly/fyjvhML 👈
#ImmunoOnc #HemOnc #Hematology #MedSky #BloodSky #HemeSky #HemeOnc
There are several important factors for physicians to consider when selecting a patient with aplastic anemia for transplantation.
Learn more from Juan Montoro in a recent interview:
👉 buff.ly/e86EdQO 👈
#Anemia #Hematology #BMTsm #EBMT25 #MedSky #BloodSky #HemeSky
Learn more from Juan Montoro in a recent interview:
👉 buff.ly/e86EdQO 👈
#Anemia #Hematology #BMTsm #EBMT25 #MedSky #BloodSky #HemeSky
April 6, 2025 at 11:00 AM
There are several important factors for physicians to consider when selecting a patient with aplastic anemia for transplantation.
Learn more from Juan Montoro in a recent interview:
👉 buff.ly/e86EdQO 👈
#Anemia #Hematology #BMTsm #EBMT25 #MedSky #BloodSky #HemeSky
Learn more from Juan Montoro in a recent interview:
👉 buff.ly/e86EdQO 👈
#Anemia #Hematology #BMTsm #EBMT25 #MedSky #BloodSky #HemeSky
Hear about advancements and promising strategies for the management of both acute and chronic #GvHD by watching our fantastic interview with Prof. Mohamad Mohty from #EBMT25! 🎥
Check it out here:
👉 buff.ly/l4g2cf2 👈
#BMTsm #HemOnc #BloodSky #HemeSky #MedSky #Hematology
Check it out here:
👉 buff.ly/l4g2cf2 👈
#BMTsm #HemOnc #BloodSky #HemeSky #MedSky #Hematology
April 5, 2025 at 9:00 AM
Hear about advancements and promising strategies for the management of both acute and chronic #GvHD by watching our fantastic interview with Prof. Mohamad Mohty from #EBMT25! 🎥
Check it out here:
👉 buff.ly/l4g2cf2 👈
#BMTsm #HemOnc #BloodSky #HemeSky #MedSky #Hematology
Check it out here:
👉 buff.ly/l4g2cf2 👈
#BMTsm #HemOnc #BloodSky #HemeSky #MedSky #Hematology
Orca-T immunotherapy reduces GVHD over conventional allogeneic #HSCT #EBMT25
sohoinsider.com/news/orca-t-...
sohoinsider.com/news/orca-t-...
Orca-T immunotherapy reduces GVHD over allogeneic HSCT
Orca-T immunotherapy reduces GVHD over conventional allogeneic HSCT in leukemia and MDS patients according to phase 3 study.
sohoinsider.com
April 5, 2025 at 1:26 AM
Orca-T immunotherapy reduces GVHD over conventional allogeneic #HSCT #EBMT25
sohoinsider.com/news/orca-t-...
sohoinsider.com/news/orca-t-...
FELIX Analysis Suggests Consolidative SCT After Obe-Cel Does Not Improve EFS/OS in R/R B-ALL #EBMT25 #oncology
www.onclive.com/view/felix-a...
www.onclive.com/view/felix-a...
FELIX Analysis Suggests Consolidative SCT After Obe-Cel Does Not Improve EFS/OS in R/R B-ALL
A small sample size from an analysis of the FELIX trial suggests consolidative SCT may not be needed after obe-cel treatment in relapsed/refractory B-ALL.
www.onclive.com
April 4, 2025 at 7:27 PM
FELIX Analysis Suggests Consolidative SCT After Obe-Cel Does Not Improve EFS/OS in R/R B-ALL #EBMT25 #oncology
www.onclive.com/view/felix-a...
www.onclive.com/view/felix-a...
We want to say a huge thank you to the organizers of #EBMT25 for having us onsite at the meeting as media partners! 😄
We have already started sharing our exclusive content from the event, with lots more to come over the coming weeks – stay tuned! 🎥🩸
👉 buff.ly/D7CceUL
#HemOnc #BloodSky #HemeSky
We have already started sharing our exclusive content from the event, with lots more to come over the coming weeks – stay tuned! 🎥🩸
👉 buff.ly/D7CceUL
#HemOnc #BloodSky #HemeSky
April 4, 2025 at 1:17 PM
We want to say a huge thank you to the organizers of #EBMT25 for having us onsite at the meeting as media partners! 😄
We have already started sharing our exclusive content from the event, with lots more to come over the coming weeks – stay tuned! 🎥🩸
👉 buff.ly/D7CceUL
#HemOnc #BloodSky #HemeSky
We have already started sharing our exclusive content from the event, with lots more to come over the coming weeks – stay tuned! 🎥🩸
👉 buff.ly/D7CceUL
#HemOnc #BloodSky #HemeSky
ICANS, Corticosteroid Use Identified As Risk Factors for NRM-Associated Infections After Axi-Cel Infusion in R/R NHL #EBMT25 #lymsm #oncology www.onclive.com/view/icans-c...
ICANS, Corticosteroid Use Identified As Risk Factors for NRM-Associated Infections After Axi-Cel Infusion in R/R NHL
Infections occur early after CAR T-cell therapy administration in patients with relapsed/refractory NHL.
www.onclive.com
April 2, 2025 at 8:31 PM
ICANS, Corticosteroid Use Identified As Risk Factors for NRM-Associated Infections After Axi-Cel Infusion in R/R NHL #EBMT25 #lymsm #oncology www.onclive.com/view/icans-c...
Dive into the impactful work of GlobalBMT at @uicdom.bsky.social! Learn how by training & working alongside doctors from low & middle income countries, the program is helping to expand access to BMT across the globe. #EBMT25 youtu.be/CS0m_emarnU
Building Bone Marrow Transplant Centers Across the Globe – University of Illinois Chicago
YouTube video by WebsEdgeMedicine
youtu.be
April 2, 2025 at 1:36 PM
Dive into the impactful work of GlobalBMT at @uicdom.bsky.social! Learn how by training & working alongside doctors from low & middle income countries, the program is helping to expand access to BMT across the globe. #EBMT25 youtu.be/CS0m_emarnU